Nkarta announces updated clinical data on anti-cd19 allogeneic car-nk cell therapy nkx019 for patients with relapsed or refractory non-hodgkin lymphoma

South san francisco, calif., dec. 05, 2022 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive updated data from its phase 1 dose escalation study of nkx019 as monotherapy to treat patients with relapsed or refractory (r/r) non-hodgkin lymphoma (nhl).
NKTX Ratings Summary
NKTX Quant Ranking